Snapshot from Sep 17, 2026 at 07:00 UTC. For live data and tracking: View Live
Business clinical milestone

Ensysce completes PF614-MPAR-102 enrollment

Analysis based on 6 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026

Sentiment
20
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The completion of enrollment is a positive clinical milestone for Ensysce, potentially boosting investor confidence in its pipeline. However, as a clinical-stage company, the impact is limited until regulatory approval and commercialization are achieved.

Biotechnology Pharmaceuticals

Forte Biosciences, a clinical-stage biotechnology company, announced completion of enrollment in the final stage (Part 3) of its PF614-MPAR-102 clinical study. The study evaluates its MPAR (Multi-Pill Abuse Resistance) overdose-protection technology, designed to limit opioid release at excessive doses while maintaining therapeutic levels at normal doses. The program has Breakthrough Therapy designation from the FDA. The study is supported by the United States — National Institute on Drug Abuse (NIDA) under award DA047682. CEO Lynn Kirkpatrick highlighted the potential to address the opioid overdose crisis, noting nearly 80,000 U.S. deaths annually. Ensysce is also developing TAAP analogues for amphetamine and methadone and a psychedelic program for Complex Regional Pain Syndrome.

90 Forte Biosciences completed enrollment
stock
Ensysce is the developer of PF614-MPAR and announced the enrollment completion, a key milestone for its lead program. The event supports its pipeline progress but does not guarantee approval or commercial success.
Importance 100.0 Sentiment 20.0
per
As CEO, Lynn Kirkpatrick is the public face of the announcement and her leadership is central to the company's progress. The event reflects positively on her management.
Importance 40.0 Sentiment 10.0
govactor
NIDA provided funding for the study, supporting the research. The event does not directly affect NIDA's operations or funding.
Importance 30.0 Sentiment 0.0
govactor
NIH, through NIDA, funded the research. The event is a positive outcome for the funded project but has no direct impact on NIH.
Importance 20.0 Sentiment 0.0
exch
Ensysce is listed on Nasdaq, and the event may influence its stock price, but Nasdaq itself is unaffected.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.